Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(159 productos)
- Bcr-Abl(115 productos)
- EGFR(594 productos)
- FAK(72 productos)
- FLT(90 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(182 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(90 productos)
- Src(81 productos)
- Syk(37 productos)
- Trombina(53 productos)
- VDA(2 productos)
- VEGFR(249 productos)
Mostrar 6 subcategorías más
Se han encontrado 2092 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Fórmula:C33H41ClN8O2Pureza:98.75%Forma y color:SolidPeso molecular:617.18N-desmethyl Regorafenib N-oxide
CAS:N-Desmethyl Regorafenib N-oxide, an active metabolite of the multi-kinase inhibitor regorafenib, originates through the action of the cytochrome P450 (CYP) isoform CYP3A4. This compound demonstrates efficacy in vitro by inhibiting key enzymes such as VEGFR2, Tie2, c-Kit, and B-RAF, and it exhibits tumor growth inhibition in HT-29 and MDA-MB-231 mouse xenograft models at a dosage of 1 mg/kg.Fórmula:C20H13ClF4N4O4Forma y color:SolidPeso molecular:484.79Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Fórmula:C42H51N9O5Forma y color:SolidPeso molecular:761.91TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Fórmula:C32H34F3N5O4Pureza:98.77%Forma y color:SolidPeso molecular:609.64VEGFR-2-IN-9
CAS:VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.Fórmula:C23H25N3O3Pureza:97.19%Forma y color:SolidPeso molecular:391.46TIE-2/VEGFR-2 kinase-IN-4
CAS:TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitoryFórmula:C26H17F4N5O4Forma y color:SolidPeso molecular:539.44DW10075
CAS:DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.Fórmula:C29H23N5O3Forma y color:SolidPeso molecular:489.52Cremastranone
CAS:Cremastranone: natural homoisoflavanone that hinders human retinal cell proliferation, migration, and tube creation.Fórmula:C18H18O7Forma y color:SolidPeso molecular:346.33HPK1-IN-2 dihydrochloride
CAS:HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46Risvodetinib
CAS:Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.Fórmula:C33H34N8O2Forma y color:SolidPeso molecular:574.68FGFR-IN-4
CAS:FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.Fórmula:C24H21N7O2Forma y color:SolidPeso molecular:439.47EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62TIE-2/VEGFR-2 kinase-IN-3
CAS:TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 valuesFórmula:C23H17F4N5O3SForma y color:SolidPeso molecular:519.47FGFR-IN-8
CAS:FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.Fórmula:C27H31Cl2N9O2Forma y color:SolidPeso molecular:584.5PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Fórmula:C23H18ClF2N3O2SPureza:98.84%Forma y color:SolidPeso molecular:473.92Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41JNJ-17029259
CAS:JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).Fórmula:C26H30N6OPureza:98%Forma y color:SolidPeso molecular:442.56PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Fórmula:C30H52N2O8Forma y color:SolidPeso molecular:568.74
